Myocardial KRASG12D expression does not cause cardiomyopathy in mice

Cardiovascular Research

Volumn 101, Issue 2, 2014, Pages 229-235

  Dalin, Martin G ^a   Zou, Zhiyuan ^a   Scharin Täng, Margareta ^a   Safari, Roghaiyeh ^a   Karlsson, Christin ^a   Bergo, Martin O ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Cardio facio cutaneous syndrome; Cardiomyopathy; KRAS; Noonan syndrome; RASopathies

Indexed keywords

ATROGIN 1; AUTOPHAGY PROTEIN 5; AUTOPHAGY PROTEIN 7; BECLIN 1; K RAS PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MUSCLE RING FINGER 1 PROTEIN; MYOSIN HEAVY CHAIN ALPHA; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOPHAGY; CAPILLARY DENSITY; CELL HYPERPLASIA; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; EMBRYO; EMBRYO DEVELOPMENT; ENZYME ACTIVATION; HEART FUNCTION; HEART MUSCLE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HEART SIZE; HISTOLOGY; HYPERTROPHIC CARDIOMYOPATHY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TISSUE SPECIFICITY; UBIQUITINATION;

CARDIO-FACIO-CUTANEOUS SYNDROME; CARDIOMYOPATHY; KRAS; NOONAN SYNDROME; RASOPATHIES;

ANIMALS; CARDIOMYOPATHY, HYPERTROPHIC, FAMILIAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENETIC PREDISPOSITION TO DISEASE; INTEGRASES; MALE; MICE; MICE, TRANSGENIC; MUTATION; MYOCARDIAL INFARCTION; MYOCARDIUM; MYOSIN HEAVY CHAINS; PHENOTYPE; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS P21(RAS); SIGNAL TRANSDUCTION; VENTRICULAR FUNCTION, LEFT; VENTRICULAR MYOSINS;

EID: 84893108212     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvt260     Document Type: Article

References (31)

1. Tidyman WE, Rauen KA. The RASopathies: Developmental syndromes of Ras/MAPK pathway dysregulation. Curr Opin Genet Dev 2009;19:230-236
2. Digilio MC, Lepri F, Baban A, Dentici ML, Versacci P, Capolino R et al. RASopathies: Clinical diagnosis in the first year of life. Mol Syndromol 2011;1:282-289
3. Moak JP, Kaski JP. Hypertrophic cardiomyopathy in children. Heart 2012;98:1044-1054
4. Hickey EJ, Mehta R, Elmi M, Asoh K, McCrindleBW, WilliamsWGet al. Survival implications: Hypertrophic cardiomyopathy in Noonan syndrome. Congenit Heart Dis 2011;6: 41-47
5. Pandit B, Sarkozy A, Pennacchio LA, Carta C, Oishi K, Martinelli S et al. Gain-of-function RAF1 mutations causeNoonan andLEOPARDsyndromes with hypertrophic cardiomyopathy. Nat Genet 2007;39:1007-1012
6. Razzaque MA, Nishizawa T, Komoike Y, Yagi H, Furutani M, Amo R et al. Germline gain-of-function mutations in RAF1 cause Noonan syndrome. Nat Genet 2007;39: 1013-1017
7. WuX, Yin J, Simpson J, Kim KH, Gu S, Hong JH et al. Increased BRAF heterodimerization is thecommon pathogenic mechanism for Noonan syndrome-associatedRAF1 mutants. Mol Cell Biol 2012;32:3872-3890
8. Wu X, Simpson J, Hong JH, Kim KH, Thavarajah NK, Backx PH et al. MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation. J Clin Invest 2011;121:1009-1025
9. Andreadi C, Cheung LK, Giblett S, Patel B, Jin H, MercerK et al. The intermediate-activity (L597V)BRAFmutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway. Genes Dev 2012;26:1945-1958
10. Urosevic J, Sauzeau V, Soto-Montenegro ML, Reig S, Desco M, Wright EM et al. Constitutive activation of B-Raf in the mouse germ line provides a model for human cardio-facio-cutaneous syndrome. Proc Natl Acad Sci USA 2011;108:5015-5020
11. Aoki Y, Niihori T, KawameH, Kurosawa K, Ohashi H, Tanaka Yet al. Germlinemutations in HRAS proto-oncogene cause Costello syndrome. Nat Genet 2005;37:1038-1040
12. Lin AE, Alexander ME, Colan SD, Kerr B, Rauen KA,Noonan J et al. Clinical, pathological, and molecular analyses of cardiovascular abnormalities in Costello syndrome: A Ras / MAPK pathway syndrome. Am J Med Genet A 2011;155 A:486-507
13. Schuhmacher AJ, Guerra C, Sauzeau V, Canamero M, Bustelo XR, Barbacid M. A mouse model for Costello syndrome reveals an Ang II-mediated hypertensive condition. J Clin Invest 2008;118:2169-2179
14. Hunter JJ, Tanaka N, Rockman HA, Ross J Jr, Chien KR. Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice. J Biol Chem 1995;270:23173-23178
15. Schubbert S, Zenker M, Rowe SL, Boll S, Klein C, Bollag G et al. Germline KRAS mutations cause Noonan syndrome. Nat Genet 2006;38:331-336
16. Niihori T, Aoki Y, Narumi Y, Neri G, Cave H, Verloes A et al. Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat Genet 2006;38:294-296
17. Zenker M, Lehmann K, Schulz AL, Barth H, Hansmann D, Koenig Ret al. Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations. J Med Genet 2007;44:131-135
18. Sala V, Gallo S, Leo C, Gatti S, Gelb BD, Crepaldi T. Signaling to cardiac hypertrophy: Insights from human and mouse RASopathies. Mol Med 2012;18:938-947
19. Tuveson DA, ShawAT, WillisNA, SilverDP, Jackson EL, Chang S et al. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 2004;5:375-387
20. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, MontoyaRet al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 2001;15:3243-3248
21. Abel ED, Kaulbach HC, Tian R, Hopkins JC, Duffy J, Doetschman T et al. Cardiac hypertrophy with preserved contractile function after selective deletion of GLUT4 from the heart. J Clin Invest 1999;104:1703-1714
22. Wahlstrom AM, Cutts BA, Liu M, Lindskog A, Karlsson C, Sjogren AK et al. Inactivating Icmt ameliorates K-RAS-induced myeloproliferative disease. Blood 2008;112: 1357-1365
23. Sjogren AK, Andersson KM, Liu M, Cutts BA, Karlsson C,WahlstromAMet al. GGTase-I deficiency reduces tumor formation and improves survival in mice with K-RAS-induced lung cancer. J Clin Invest 2007;117:1294-1304
24. Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, Liao R et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 2005;115:2108-2118
25. Gelb BD, Tartaglia M. RAS signaling pathway mutations and hypertrophic cardiomyopathy: Getting into and out of the thick of it. J Clin Invest 2011;121:844-847
26. Marin TM, Keith K, Davies B, Conner DA, Guha P, KalaitzidisDet al. Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. J Clin Invest 2011;121:1026-1043
27. Ceci M, Gallo P, Santonastasi M, Grimaldi S, LatronicoMV, Pitisci Aet al.Cardiac-specific overexpression of E40K active Akt prevents pressure overload-induced heart failure in mice by increasing angiogenesis and reducing apoptosis. Cell Death Differ 2007;14: 1060-1062
28. Matsui T, Tao J, del Monte F, Lee KH, Li L et al. Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation 2001;104: 330-335
29. Sussman MA, Volkers M, Fischer K, Bailey B, CottageCT, Din S et al. Myocardial AKT: The omnipresent nexus. Physiol Rev 2011;91:1023-1070
30. Garcia JM, Gonzalez R, Silva JM, Dominguez G, Vegazo IS, Gamallo C et al. Mutational status of K-ras and TP53 genes in primary sarcomas of the heart. Br J Cancer 2000;82: 1183-1185
31. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003;4:437-450